Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Rating of “Hold” from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been given a consensus recommendation of “Hold” by the five research firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $20.3333.

Several research analysts have recently commented on the company. Weiss Ratings downgraded Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Ascendiant Capital Markets cut their price target on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a report on Friday, April 10th. Finally, Rodman & Renshaw began coverage on shares of Atossa Genetics in a research report on Tuesday, July 7th. They set a “buy” rating and a $12.00 price objective for the company.

Atossa Genetics Stock Performance

Shares of ATOS stock opened at $2.36 on Friday. Atossa Genetics has a 52-week low of $1.70 and a 52-week high of $19.35. The stock has a market cap of $20.32 million, a price-to-earnings ratio of -0.74 and a beta of 1.29. The firm’s 50-day moving average is $2.62 and its 200-day moving average is $4.51.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.07. Sell-side analysts predict that Atossa Genetics will post -4.3 EPS for the current fiscal year.

Institutional Trading of Atossa Genetics

A number of hedge funds have recently modified their holdings of the stock. Graham Capital Management L.P. grew its stake in Atossa Genetics by 27.8% in the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after buying an additional 45,923 shares during the last quarter. State Street Corp lifted its position in Atossa Genetics by 31.2% during the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after acquiring an additional 141,990 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Atossa Genetics by 55.8% during the third quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock worth $135,000 after acquiring an additional 55,568 shares during the period. Squarepoint Ops LLC boosted its holdings in shares of Atossa Genetics by 39.9% during the third quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock worth $220,000 after acquiring an additional 72,235 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Atossa Genetics during the second quarter worth approximately $381,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.